30 results about "Celecoxib" patented technology

The application relates to a celecoxib capsule composition and belongs to the technical field of pharmaceutical preparations. The celecoxib capsule composition is prepared from the following components in percentage by weight: celecoxib 74.1%, lactose monohydrate 16.4%-17.4%, arginine 1.0%-2.0%, sodium dodecyl sulfate 3.0%, povidone (K30) 2.5%, cross-linked sodium carboxymethyl cellulose 1.0%, and magnesium stearate 1.0%. The problem that the dissolution curve of the celecoxib capsule is significantly slowed down during storage is solved by adding appropriate arginine in the prescription.

The application belongs to the technical field of wound dressings, and discloses a water-based gel dressing with antibacterial and scar prevention effects and a preparation method, wherein 3-fluoro-4-carboxyphenylboronic acid is introduced to graft chitooligosaccharide, a large number of catechol structures in tannic acid solution are combined with the phenylboronic acid bond to form a dynamic boron ester bond, and a network gel structure is formed by responding to the supermolecular forces such as hydrogen bonds, wherein the boron ester bond can be broken in response to the high ROS level of the wound microenvironment and the acidic environment caused by bacterial infection, so as to efficiently release celecoxib, a selective non-steroidal anti-inflammatory drug of cyclooxygenase-2, and the liposome of verteporfin is limited in volume and stays in the dressing for a longer time, so that the sustained and stable release can be maintained in the whole wound healing process, thereby achieving the effects of on-demand inflammation regulation and long-acting mechanical response regulation.

The present invention provides a celecoxib cream and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, the celecoxib cream comprises, by mass, 0.5%-2% of celecoxib, 1%-20% of an oily matrix, 1%-20% of an emulsifier, 0.1%-10% of a transdermal absorption enhancer, 1%-20% of a thickener, 2%-15% of a humectant, 0.1%-2% of a preservative, 0.1%-10% of a pH regulator, and the balance of deionized water. The prepared celecoxib cream is good in stability and high in bioavailability, and gastrointestinal reaction and oral first pass effect of a traditional oral dosage form are avoided. The celecoxib cream disclosed by the invention is also added with a transdermal absorption enhancer, so that medicine molecules can be helped to penetrate through a skin barrier and directly reach a focus part; the metabolism loss of the medicine on the skin surface can be reduced, more active ingredients enter blood circulation or deep tissues, the local treatment effect is enhanced, and the important clinical value is achieved.

An embodiment relates to a tablet comprising celecoxib, and ciprofloxacin or a pharma- ceutically acceptable salt thereof, and a low viscosity hydroxypropyl methylcellulose having a viscosity of less than 150 cP when measured as a 2% solution in water at 20°C.

The present invention relates to a pharmaceutical composition which comprises the synergistic combination of a selective inhibitor of cyclooxygenase-2, such as the active ingredient: celecoxib and its pharmaceutically acceptable salts, and a carbamate derived from guaifenesin, such as the active ingredient: methocarbamol and its pharmaceutically acceptable salts, which are formulated with pharmaceutically acceptable excipients and / or carriers and / or additives in a single dosage unit to be orally, dermally or transdermally or topically administered, which is also indicated in the treatment of pain, inflammation and muscular contractions, wherein said combination has a triple analgesic, anti-inflammatory and muscle-relaxing effect, and is better tolerated and has less side effects in patients with pain, inflammation and muscular contraction.

The present disclosure relates to methods of treating Alzheimer's disease, diseases and / or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.

The invention discloses an application of celecoxib or a pharmaceutical salt thereof in preparation of an antifungal drug synergist. An antifungal drug is selected from an azole antifungal drug, an allylamine antifungal drug or an echinocandin antifungal drug. The azole antifungal drug is selected from the group consisting of fluconazole, voriconazole, itraconazole, posaconazole and isavuconazole; the allylamine antifungal drug is selected from terbinafine; the echinocandin antifungal drug is selected from caspofungin. In-vivo and in-vitro experiments prove that when the celecoxib is combined with the azole antifungal drug and the allylamine antifungal drug terbinafine, a synergistic antifungal effect is shown, and when the celecoxib is combined with the echinocandin antifungal drug caspofungin, an additive effect is shown. Celecoxib and fluconazole are combined for use, so that the survival rate of fungal infected animals can be increased, and toxicity to wax moth larvae and mammalian cells is low.

The present application relates to a celecoxib-vitamin E prodrug. The celecoxib-vitamin E prodrug is prepared by connecting celecoxib with vitamin E by means of a dithio-bis-acetic acid. The catalysts used include: dicyclohexyl carbodiimide (DCC), 4-dimethylaminopyridine (DMAP). The prodrug has some characteristics: uniform distribution in a spherical shape, the average particle size is about 700 nm, the drug loading can reach 4 mg•mL ‑1 The prodrug can improve the bioavailability of celecoxib, and the preparation method thereof is disclosed.

This disclosure relates to methods for treating diseases and / or conditions (including long COVID) associated with Covid-19 infection, the methods comprising administering a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nematvir and ritonavir, monorapvir, a BCG vaccine, or ivermectin.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a celecoxib tablet and a preparation method thereof.The celecoxib tablet is composed of celecoxib, lactose-microcrystalline cellulose compounded according to a specific proportion, polyvinylpolypyrrolidone-carboxymethyl starch sodium, a lubricant and a solubilizing stabilizer. Wherein the solubilizing stabilizer is beta-cyclodextrin, sodium stearoyl lactylate and meglumine. The preparation method comprises the steps of pretreatment of the celecoxib and the solubilizing stabilizer, step-by-step granulation, drying and size stabilization, and total mixing and tabletting. Through the synergistic effect of the compound solubilizing stabilizer and the wet grinding process and in combination with the preparation method of step-by-step mixing granulation, the content uniformity, the dissolution performance and the storage stability of the prepared celecoxib tablet are remarkably improved, and the preparation process is simple and easy to operate and suitable for industrial large-scale production.

The scheme discloses a triple-negative breast cancer targeting drug and preparation and application, proposes a combination drug of paclitaxel and celecoxib, and uses a polypeptide modified liposome to deliver the combination drug, realizes target co-delivery of the combination drug, and improves the effectiveness of ICD and the rejection of the anti-tumor immune response in triple-negative breast cancer through the joint action of paclitaxel and celecoxib in a reasonable proportion, and the experiment proves that the combination drug has good therapeutic effect and recurrence and metastasis inhibition effect.

The invention relates to the technical field of biology, in particular to novel application of sanguinarine (SAN), a method for inducing human amniotic mesenchymal stem cells (hAMSCs) to be differentiated into osteoblasts through COX2 protein and an osteogenic induction culture medium for the inducing method, and the method can be applied to the fields of bone disease treatment drug research and development and clinical transformation. It is proved for the first time that SAN mediates hAMSCs osteogenic differentiation through COX2 protein, SAN can significantly improve expression of COX2 gene (PTGS2) in hAMSCs, the osteogenic effect of SAN can be reversed by adding a COX2 inhibitor (such as celecoxib), and direct experimental evidence is provided for'COX2 serving as a small molecule drug to promote osteogenic differentiation '.

The present disclosure relates to use of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the present disclosure is used for treating inflammatory depression, wherein the pharmaceutical composition comprises: (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition of the present disclosure is directed to inflammatory depression (especially inflammatory treatment-resistant depression and anhedonia depression).

The application relates to the technical field of medicines, and particularly discloses a class of celecoxib derivatives, a preparation method and application thereof. The derivative is formed by connecting celecoxib and straight-chain amino acids through a chemical bond, and the straight-chain amino acids are glycine, gamma-aminobutyric acid and the like. The derivative or a pharmaceutically acceptable salt and a pharmaceutical composition thereof can be used for preparing medicines for preventing and / or treating pain or nervous system diseases. The derivative has excellent water solubility, strong COX-2 inhibitory activity, good analgesic activity and anti-inflammatory activity, has good analgesic effects on inflammatory pain, neuropathic pain and visceral pain and the like, and has a wide application prospect.

The invention provides an osteoarthritis analgesic enteric capsule containing a non-steroidal anti-inflammatory component, and relates to the technical field of pharmaceutical preparations. The osteoarthritis analgesic enteric capsule containing the non-steroidal anti-inflammatory component comprises an enteric capsule shell and a content, and is characterized in that the content comprises iguratimod and celecoxib which serve as active components, and the content is composed of two independent enteric coated pellets: A type pellets, B type pellets, C type pellets and D type pellets, comprising a celecoxib-containing drug-loaded pellet core and an enteric coating layer coating the celecoxib-containing drug-loaded pellet core, the B-type pellet comprises a drug-loaded pellet core containing iguratimod and an enteric coating layer coating the drug-loaded pellet core; the A-type pellets and the B-type pellets are physically mixed according to a certain proportion and then are filled in the same enteric capsule shell. Celecoxib and iguratimod are adopted, Celecoxib provides rapid and powerful pain relief, iguratimod inhibits inflammation pathways from multiple targets and provides cartilage protection, and the combination of Celecoxib and iguratimod realizes the synergistic effect of treating both symptoms and root causes.

This invention discloses a ternary nanoparticle, its preparation method, and its applications, relating to the field of biomedical technology. The invention constructs a carrier-free, fully active ternary nanoparticle (diPCL NPs). This nanoplatform connects PTX dimer (diPTX), celecoxib (CXB) dimer (diCXB), and lonidamine (LND) dimer (diLND) via disulfide bonds for chemoimmunotherapy of drug-resistant tumors. diPCL NPs accumulate at tumor sites through enhanced permeability and retention (EPR) effects and circulate continuously in the bloodstream. In the high GSH tumor microenvironment, disulfide bond cleavage releases the active drug, exerting chemotherapeutic, immune-activating, sensitizing, and metabolic-regulating effects. diPCL NPs exhibit high antitumor efficacy and good safety profile within the therapeutic window in both breast cancer and paclitaxel-resistant models.

The application belongs to the technical field of medical devices, and specifically discloses an anti-tumor electrospun scaffold and a preparation method thereof. The anti-tumor electrospun scaffold comprises a drug-loaded electrospun scaffold body and tumor cell-derived drug-loaded micro-particles loaded on the surface of the scaffold body. The drug-loaded electrospun scaffold body comprises amino polymers, hydrophilic polymers and celecoxib with a mass ratio of (2-10):(2-13):1, which are prepared by using an electrospinning technology, and has a high specific surface area and a high porosity. The loading amount of the tumor cell-derived doxorubicin-loaded micro-particles on the anti-tumor electrospun scaffold is 0.6 μg / mg-6.1 μg / mg. The drug is directly delivered to a tumor resection cavity in the form of in-situ implantation, long-term drug retention, continuous drug release and complete degradation of the scaffold material are achieved. Residual tumor cells are effectively killed, the tumor immune microenvironment is reshaped, and the recurrence and metastasis of the tumor are inhibited.

The invention belongs to the technical field of biological medicines, and discloses a polydopamine modified celecoxib and cisplatin loaded dual drug-loading microsphere, which takes a polydopamine modified polyvinyl alcohol microsphere as a carrier, and the surface of the microsphere is loaded with celecoxib and cisplatin. Celecoxib and cis-platinum loaded on the dual drug-loading microspheres prepared by the invention have a good synergistic effect, and can significantly inhibit the excessive growth of liver cancer in blood vessels; when being applied to the liver cancer TACE operation, the compound has relatively high safety and high operation success rate, and can remarkably inhibit tumor cell proliferation so as to improve the embolization chemotherapy effect. The invention also discloses a preparation method of the dual drug-loading microsphere.

The invention discloses an application of a halophenol compound 2, 4 ', 5'-trihydroxy-5, 2 '-dibromo benzophenone as a medicament for resisting rheumatoid arthritis. The compound can effectively relieve the ankle joint swelling degree of rheumatoid arthritis rats, relieve cartilage injury and reduce the arthritis score, main treatment indexes such as MMP-9, IL-17A, IL-1beta and IgM are all superior to those of a clinical medicine celecoxib, the reduction of the spleen coefficient is remarkably superior to that of celecoxib, and the important application prospect in the aspect of treating rheumatoid arthritis is shown.

This disclosure provides a pharmaceutical composition, a kit, and its use. The pharmaceutical composition provided in this disclosure comprises deuterated dextromethorphan or a salt thereof and celecoxib.

This invention provides a biodegradable microsphere, wherein the microsphere (i) has a diameter of from 1 ?m to 500 ?m; (ii) comprises a polylactic-co-glycolic acid copolymer (PLGA) matrix; (iii) carries pharmaceutical celecoxib; and (iv) when present in a suitable joint-related tissue, releases celecoxib for at least one month. This invention also provides related injectable formulations, methods for treating joint-related disorders, and kits.

1. Name of the designed product: packing box (capsule of celecoxib). 2. Use of the designed product: for packing product. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo showing the design points: perspective view.

The present application relates to a method of providing a therapeutic regimen for the treatment of pain, wherein said method comprises administering an oral liquid pharmaceutical composition comprising celecoxib or a pharmaceutically acceptable salt thereof to a subject in need thereof.

The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.

The present application relates to a kind of celecoxib-vitamin E prodrug nano drug delivery system preparation based on electrostatic spray.The dithio-bis-acetic acid is used to connect celecoxib (CEL) with vitamin E (VE), and the celecoxib-vitamin E prodrug (CEL-SVE) is prepared.On this basis, the celecoxib-vitamin E prodrug nanoparticle (CEL-SVE NPs) is further prepared.The prodrug nanoparticle has some characteristics: the average particle size is less than 400 nm, is uniformly distributed in the form of spherical shape, and the drug loading can reach 6 mg•mL ‑1 Under acidic conditions, it is gradually hydrolyzed, and is relatively stable under pH 7.4 conditions.The prodrug nanoparticle can increase the solubility of celecoxib, significantly improve the bioavailability of celecoxib, increase the targeting effect of celecoxib on tumor cells, and significantly improve the anticancer and anti-inflammatory analgesic efficacy of celecoxib.It has good stability, high safety, and great market prospect.

The invention belongs to the technical field of pharmaceutical chemicals, and particularly relates to a preparation method of a low-water-content celecoxib dione intermediate. The method comprises the following steps: under the action of sodium methoxide, ethyl trifluoroacetate and p-methylacetophenone react in methanol, the temperature is controlled to be 20-30 DEG C after the reaction is finished, purified water is added into a system, an acid aqueous solution is dropwise added to adjust the pH value of feed liquid to be 2-5, crystallization is performed, and the celecoxib dione intermediate is obtained. The celecoxib dione intermediate obtained by the invention has larger crystal particles and better dispersity, is easy to filter, and reduces the moisture content of a wet product, so that the time required for drying is shortened, and the cost is saved for actual production.

The invention provides an application of celecoxib in preparation of a medicament for treating olfactory disorder, relates to the technical field of biomedicine, and is technically characterized in that the application of celecoxib in preparation of a medicament for treating olfactory disorder is provided, a non-steroidal anti-inflammatory medicament, namely celecoxib, is a selective inhibitor of epoxidase-2, and can be used for preparing a medicament for treating olfactory disorder. The traditional Chinese medicine composition is mainly used for treating osteoarthritis and rheumatoid arthritis. The COX-2 is a rate-limiting enzyme for synthesizing prostaglandin, and the expression level of the COX-2 is up-regulated when an organism is subjected to harmful stimulation (such as inflammation, oxidative stress, autoimmune response, mechanical injury and the like) and is induced by a transforming growth factor TGF-beta. In addition to regulating inflammatory response, the compound also can participate in regulating cell growth, migration, proliferation, autophagy and apoptosis. An olfactory dysfunction model induced by methimazole (MMI) is established, and the potential treatment effect of the celecoxib on the olfactory dysfunction is provided on the basis of behavioral and histological experiments, so that the celecoxib can be proved to be capable of preparing the medicine for treating the olfactory dysfunction.